Medicare does not work as one decision. It works as a set of rules, applied by a specific plan, to a specific prescription written for a specific reason. Two people on the same medicine can get different answers, and both answers can be correct under the rules.
Important safety information. Semaglutide is the active ingredient in Ozempic and Wegovy, FDA-approved prescription medicines from Novo Nordisk A/S. Tirzepatide is the active ingredient in Mounjaro and Zepbound, from Eli Lilly and Company. These branded medicines carry a boxed warning about the risk of thyroid C-cell tumors. They should not be used by people with a personal or family history of medullary thyroid carcinoma, or by people with Multiple Endocrine Neoplasia syndrome type 2. Serious risks can include pancreatitis, gallbladder problems, acute kidney injury, severe stomach and intestinal reactions, serious allergic reactions, low blood sugar when taken with certain other diabetes medicines, and diabetic retinopathy complications. Read the official Prescribing Information and Medication Guide for each: Ozempic, Wegovy, Mounjaro, and Zepbound.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Which part of Medicare is even involved
Outpatient prescriptions you pick up at a pharmacy generally fall under Part D, which is delivered by private plans, including the drug benefit inside many Medicare Advantage plans. Part B covers a different set of items, mostly things administered in a clinical setting or supplied as durable medical equipment.
That matters because a self-administered injection filled at a pharmacy is normally a Part D question, and Part D is a plan-by-plan question. There is no single national answer to give.
The weight-loss exclusion, in plain language
Part D was written with a list of drug categories that plans are not required to include. One item on that list, carried into Part D by the Social Security Act at section 1860D-2(e)(2)(A) through the list at section 1927(d)(2), is agents when used for weight loss.
Read that carefully, because the phrase that does the work is "when used for." The exclusion is about the use the prescription is written for, not about the molecule itself.
CMS has since addressed the situation where a medicine that would be excluded for weight loss also carries another medically accepted indication that FDA has approved. In that situation the medicine can be treated as a Part D drug for that other indication. CMS publishes its Part D guidance and manuals on cms.gov, and that is the source to read rather than a summary of it.
The practical consequence is that the prescribing reason, the diagnosis coding, and the documentation in the chart carry real weight in how a plan processes the claim.
What an individual plan still controls
Even where a medicine can be a Part D drug, the plan decides its own formulary and its own utilization rules. Common ones are prior authorization, step therapy, quantity limits, and preferred pharmacy arrangements. Plans also change these between plan years.
So there are two layers. The program rules say what is eligible to be covered at all. The plan rules say what this plan does about it this year.
You can read both. Every Part D plan publishes a formulary and its coverage criteria, and the Medicare Plan Finder lets you check a specific drug against specific plans during enrollment periods.
Questions to ask, and how to ask them
Call the number on the member card and ask member services these, one at a time. Record the answers and the date.
- Is this exact prescription on the current formulary, for the indication my clinician is treating?
- What prior authorization or coverage criteria apply, and what documentation does the prescriber need to submit?
- Are there quantity limits or step therapy requirements?
- Which pharmacies are preferred or in network for it?
- What is the cost sharing at each coverage stage this year?
If a request is denied, Medicare has a defined appeals process with deadlines, and your plan must tell you how to use it. A denial at the first step is not the end of the process, and the reason given in the notice tells the prescriber what to address.
Nothing on this page predicts an outcome. Approval and payment are determined by the plan under its own terms.
Where compounded medications sit
Compounded semaglutide and compounded tirzepatide are prepared by a pharmacy for an individual patient. They are not finished, approved drug products, and Part D coverage is built around approved drug products, so these preparations do not sit on a Part D formulary.
Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness, or manufacturing quality.
A compounded preparation is not Zepbound, not Mounjaro, not Ozempic and not Wegovy. It is not a generic version of any approved drug, and it is not interchangeable with one. FDA's overview of human drug compounding explains the category.
It may be dispensed only pursuant to a valid prescription issued by a licensed clinician after a clinical evaluation, and only from a state-licensed pharmacy.
One more point for people with Medicare. If you pay for something outside the plan, that spending generally does not count toward your plan's cost-sharing totals. Confirm that with your plan before assuming either way.
Body Good service fees, stated plainly
Body Good's prices are service fees for the program described at intake. They cover the clinical evaluation and the ongoing care and support in that program. They are not the price of medication and are not a quote for any individual. Eligibility is determined by a clinician.
A Body Good service fee does not include the cost of medication. The pharmacy bills for what it dispenses and a laboratory bills for its own work.
Body Good provides coverage support, which means help checking benefits and preparing paperwork a plan requests. It does not determine what a plan approves or pays, and it does not sell or administer any Medicare plan.
This site is an information and pricing overview only. It takes no payment, collects no health information, and runs no intake form. Intake happens on joinbodygood.com.
Frequently asked questions
Does Medicare treat these medicines as weight-loss drugs automatically?
No. The Part D exclusion turns on the use a prescription is written for. A medicine with another FDA-approved indication can be handled differently, and your plan applies its own formulary and criteria on top of that.
Can a Medicare plan pay for a compounded version?
Part D coverage is built around approved drug products, and compounded preparations are not approved drug products, so they are not on a Part D formulary. Ask your plan directly about any specific situation.
What does Body Good's fee cover for someone on Medicare?
The same thing it covers for anyone: the clinical program described at intake. Medication and laboratory charges are separate. Begin Body Good's clinical intake to have a clinician review your situation.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.